Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
goserelin + dutasteride
- Development stage
- Unknown
- Lead developer
- AstraZeneca
- Modality
- Peptides, Small Molecules
- Administration
- Subcutaneous, Oral
01
Overview
Goserelin + dutasteride is a combination of two pharmaceutical agents used primarily in the management of hormone-sensitive cancers, particularly prostate cancer. Goserelin is a synthetic decapeptide analog of gonadotropin-releasing hormone (GnRH) that acts as an agonist at the GnRH receptor, leading to sustained suppression of pituitary gonadotropin secretion and subsequent reduction in testosterone production in men or estradiol production in women[2][6]. Dutasteride is a small molecule inhibitor of 5-alpha-reductase, the enzyme responsible for converting testosterone to dihydrotestosterone (DHT), thereby reducing DHT levels and further suppressing androgenic stimulation[1][8]. The combination aims to achieve maximal androgen deprivation by targeting both upstream hormonal signaling (goserelin) and downstream androgen conversion (dutasteride). This dual approach may be used for advanced or recurrent prostate cancer and has been studied in other hormone-driven malignancies[4].
- Brand names
- Duodart
- Other names
- goserelin acetate
02
Targets
SRD5A3 (Steroid 5α-reductase 3)GnRHR (Gonadotropin-releasing hormone receptor)SRD5A2 (Steroid 5-alpha-reductase type II)SRD5A1 (Steroid 5-alpha-reductase type 1)
Beyond the preview
Go deeper on goserelin + dutasteride.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on goserelin + dutasteride.